{"pmid":32363136,"pmcid":"PMC7194921","title":"Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.","text":["Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites.","The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continually led to worldwide human infections and deaths. Currently, there is no specific viral protein-targeted therapeutics. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural information of SARS-CoV-2 nucleocapsid protein remains unclear. Herein, we have determined the 2.7 A crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein. Although the overall structure is similar as other reported coronavirus nucleocapsid protein N-terminal domain, the surface electrostatic potential characteristics between them are distinct. Further comparison with mild virus type HCoV-OC43 equivalent domain demonstrates a unique potential RNA binding pocket alongside the beta-sheet core. Complemented by in vitro binding studies, our data provide several atomic resolution features of SARS-CoV-2 nucleocapsid protein N-terminal domain, guiding the design of novel antiviral agents specific targeting to SARS-CoV-2.","Acta Pharm Sin B","Kang, Sisi","Yang, Mei","Hong, Zhongsi","Zhang, Liping","Huang, Zhaoxia","Chen, Xiaoxue","He, Suhua","Zhou, Ziliang","Zhou, Zhechong","Chen, Qiuyue","Yan, Yan","Zhang, Changsheng","Shan, Hong","Chen, Shoudeng","32363136"],"abstract":["The outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus continually led to worldwide human infections and deaths. Currently, there is no specific viral protein-targeted therapeutics. Viral nucleocapsid protein is a potential antiviral drug target, serving multiple critical functions during the viral life cycle. However, the structural information of SARS-CoV-2 nucleocapsid protein remains unclear. Herein, we have determined the 2.7 A crystal structure of the N-terminal RNA binding domain of SARS-CoV-2 nucleocapsid protein. Although the overall structure is similar as other reported coronavirus nucleocapsid protein N-terminal domain, the surface electrostatic potential characteristics between them are distinct. Further comparison with mild virus type HCoV-OC43 equivalent domain demonstrates a unique potential RNA binding pocket alongside the beta-sheet core. Complemented by in vitro binding studies, our data provide several atomic resolution features of SARS-CoV-2 nucleocapsid protein N-terminal domain, guiding the design of novel antiviral agents specific targeting to SARS-CoV-2."],"journal":"Acta Pharm Sin B","authors":["Kang, Sisi","Yang, Mei","Hong, Zhongsi","Zhang, Liping","Huang, Zhaoxia","Chen, Xiaoxue","He, Suhua","Zhou, Ziliang","Zhou, Zhechong","Chen, Qiuyue","Yan, Yan","Zhang, Changsheng","Shan, Hong","Chen, Shoudeng"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363136","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.apsb.2020.04.009","keywords":["antiviral targeting site","covid-19","coronavirus","crystal structure","nucleocapsid protein","rna binding domain","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496012648449,"score":9.490897,"similar":[{"pmid":32266867,"title":"In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain).","text":["In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain).","The N terminal domain (NTD) of Nucleocapsid protein (N protein) of coronavirus (CoV) binds to the viral (+) sense RNA and results in CoV ribonucleoprotien (CoV RNP) complex, essential for the virus replication. In this study, the RNA-binding N terminal domain (NTD) of the N protein was targeted for the identification of possible inhibitors of RNA binding. Two NTD structures of N proteins were selected (2OFZ and 1SSK, 92% homology) for virtual screening of 56,079 compounds from Asinex and Maybridge library to identify top 15 hits for each of the targets based on \"docking score\". These top-hits were further screened for MM-GBSA binding free energy, pharmacokinetic properties (QikProp) and drug-likeness (SwissADME) and subjected to molecular dynamics (MD) studies. Two suitable binders (ZINC00003118440 and ZINC0000146942) against the target 2OFZ were identified. ZINC00003118440 is a theophylline derivative under the drug class 'bronchodilEtors' and further screening with approved bronchodilators was also studied to identify their ability to bind to the RNA binding region on the N protein. The other identified top hit is ZINC0000146942, which is a 3,4dihydropyrimidone class molecule. Hence this study suggests two important class of compounds, theophylline and pyrimidone derivaties as possible inhibitors of RNA binding to the N terminal domain of N protein of coronavirus, thus opening new avenues for in vitro validations.","J Biomol Struct Dyn","Sarma, Phulen","Sekhar, Nishant","Prajapat, Manisha","Avti, Pramod","Kaur, Hardeep","Kumar, Subodh","Singh, Sanjay","Kumar, Harish","Prakash, Ajay","Dhibar, Deba Prasad","Medhi, Bikash","32266867"],"abstract":["The N terminal domain (NTD) of Nucleocapsid protein (N protein) of coronavirus (CoV) binds to the viral (+) sense RNA and results in CoV ribonucleoprotien (CoV RNP) complex, essential for the virus replication. In this study, the RNA-binding N terminal domain (NTD) of the N protein was targeted for the identification of possible inhibitors of RNA binding. Two NTD structures of N proteins were selected (2OFZ and 1SSK, 92% homology) for virtual screening of 56,079 compounds from Asinex and Maybridge library to identify top 15 hits for each of the targets based on \"docking score\". These top-hits were further screened for MM-GBSA binding free energy, pharmacokinetic properties (QikProp) and drug-likeness (SwissADME) and subjected to molecular dynamics (MD) studies. Two suitable binders (ZINC00003118440 and ZINC0000146942) against the target 2OFZ were identified. ZINC00003118440 is a theophylline derivative under the drug class 'bronchodilEtors' and further screening with approved bronchodilators was also studied to identify their ability to bind to the RNA binding region on the N protein. The other identified top hit is ZINC0000146942, which is a 3,4dihydropyrimidone class molecule. Hence this study suggests two important class of compounds, theophylline and pyrimidone derivaties as possible inhibitors of RNA binding to the N terminal domain of N protein of coronavirus, thus opening new avenues for in vitro validations."],"journal":"J Biomol Struct Dyn","authors":["Sarma, Phulen","Sekhar, Nishant","Prajapat, Manisha","Avti, Pramod","Kaur, Hardeep","Kumar, Subodh","Singh, Sanjay","Kumar, Harish","Prakash, Ajay","Dhibar, Deba Prasad","Medhi, Bikash"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266867","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1080/07391102.2020.1753580","keywords":["2019 novel corona virus","2019-ncov","n terminal domain","nucleocapsid protein","rna binding","sars-cov-2","drug design"],"locations":["Nucleocapsid"],"e_drugs":["Pyrimidinones","Theophylline"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491982970880,"score":646.01044},{"pmid":32275855,"pmcid":"PMC7144619","title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","text":["Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.","Cell","Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun","32275855"],"abstract":["The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus."],"journal":"Cell","authors":["Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275855","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.cell.2020.03.045","keywords":["ace2","ctd","sars-cov-2","crystal structure","immunogenicity","receptor","receptor binding domain"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491701952513,"score":503.95282},{"pmid":32105468,"pmcid":"PMC7094172","title":"Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.","text":["Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.","Structure-based stabilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery. However, this approach has mainly focused on the stabilization of native PPIs, and non-native PPIs have received little consideration. Here, we identified a non-native interaction interface on the three-dimensional dimeric structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD). The interface formed a conserved hydrophobic cavity suitable for targeted drug screening. By considering the hydrophobic complementarity during the virtual screening step, we identified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities. X-ray crystallography and small-angle X-ray scattering showed that 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell. This unique approach based on the identification and stabilization of non-native PPIs of N protein could be applied toward drug discovery against CoV diseases.","J Med Chem","Lin, Shan-Meng","Lin, Shih-Chao","Hsu, Jia-Ning","Chang, Chung-Ke","Chien, Ching-Ming","Wang, Yong-Sheng","Wu, Hung-Yi","Jeng, U-Ser","Kehn-Hall, Kylene","Hou, Ming-Hon","32105468"],"abstract":["Structure-based stabilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery. However, this approach has mainly focused on the stabilization of native PPIs, and non-native PPIs have received little consideration. Here, we identified a non-native interaction interface on the three-dimensional dimeric structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD). The interface formed a conserved hydrophobic cavity suitable for targeted drug screening. By considering the hydrophobic complementarity during the virtual screening step, we identified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities. X-ray crystallography and small-angle X-ray scattering showed that 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell. This unique approach based on the identification and stabilization of non-native PPIs of N protein could be applied toward drug discovery against CoV diseases."],"journal":"J Med Chem","authors":["Lin, Shan-Meng","Lin, Shih-Chao","Hsu, Jia-Ning","Chang, Chung-Ke","Chien, Ching-Ming","Wang, Yong-Sheng","Wu, Hung-Yi","Jeng, U-Ser","Kehn-Hall, Kylene","Hou, Ming-Hon"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32105468","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1021/acs.jmedchem.9b01913","e_drugs":["5-benzyloxygramine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490789691392,"score":464.57938},{"pmid":32251731,"pmcid":"PMC7128678","title":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.","text":["Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.","The recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) is responsible for a worldwide pandemic. Given the global health emergency, drug repositioning is the most reliable option to design an efficient therapy for infected patients without delay. The first step of the viral replication cycle [i.e. attachment to the surface of respiratory cells, mediated by the spike (S) viral protein] offers several potential therapeutic targets. The S protein uses the angiotension-converting enzyme-2 (ACE-2) receptor for entry, but also sialic acids linked to host cell surface gangliosides. Using a combination of structural and molecular modelling approaches, this study showed that chloroquine (CLQ), one of the drugs currently under investigation for SARS-CoV-2 treatment, binds sialic acids and gangliosides with high affinity. A new type of ganglioside-binding domain at the tip of the N-terminal domain of the SARS-CoV-2 S protein was identified. This domain (111-158), which is fully conserved among clinical isolates worldwide, may improve attachment of the virus to lipid rafts and facilitate contact with the ACE-2 receptor. This study showed that, in the presence of CLQ [or its more active derivative, hydroxychloroquine (CLQ-OH)], the viral S protein is no longer able to bind gangliosides. The identification of this new mechanism of action of CLQ and CLQ-OH supports the use of these repositioned drugs to cure patients infected with SARS-CoV-2. The in-silico approaches used in this study might also be used to assess the efficiency of a broad range of repositioned and/or innovative drug candidates before clinical evaluation.","Int J Antimicrob Agents","Fantini, Jacques","Di Scala, Coralie","Chahinian, Henri","Yahi, Nouara","32251731"],"abstract":["The recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) is responsible for a worldwide pandemic. Given the global health emergency, drug repositioning is the most reliable option to design an efficient therapy for infected patients without delay. The first step of the viral replication cycle [i.e. attachment to the surface of respiratory cells, mediated by the spike (S) viral protein] offers several potential therapeutic targets. The S protein uses the angiotension-converting enzyme-2 (ACE-2) receptor for entry, but also sialic acids linked to host cell surface gangliosides. Using a combination of structural and molecular modelling approaches, this study showed that chloroquine (CLQ), one of the drugs currently under investigation for SARS-CoV-2 treatment, binds sialic acids and gangliosides with high affinity. A new type of ganglioside-binding domain at the tip of the N-terminal domain of the SARS-CoV-2 S protein was identified. This domain (111-158), which is fully conserved among clinical isolates worldwide, may improve attachment of the virus to lipid rafts and facilitate contact with the ACE-2 receptor. This study showed that, in the presence of CLQ [or its more active derivative, hydroxychloroquine (CLQ-OH)], the viral S protein is no longer able to bind gangliosides. The identification of this new mechanism of action of CLQ and CLQ-OH supports the use of these repositioned drugs to cure patients infected with SARS-CoV-2. The in-silico approaches used in this study might also be used to assess the efficiency of a broad range of repositioned and/or innovative drug candidates before clinical evaluation."],"journal":"Int J Antimicrob Agents","authors":["Fantini, Jacques","Di Scala, Coralie","Chahinian, Henri","Yahi, Nouara"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251731","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijantimicag.2020.105960","keywords":["chloroquine","coronavirus","ganglioside","pandemic","sars-cov-2","spike"],"e_drugs":["Hydroxychloroquine","Chloroquine","Lipids","Gangliosides","Sialic Acids"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491029815296,"score":431.51035},{"pmid":32416961,"title":"Biochemical characterization of SARS-CoV-2 nucleocapsid protein.","text":["Biochemical characterization of SARS-CoV-2 nucleocapsid protein.","The nucleocapsid (N) protein is an important antigen for coronavirus, which participate in RNA package and virus particle release. In this study, we expressed the N protein of SARS-CoV-2 and characterized its biochemical properties. Static light scattering, size exclusive chromatography, and small-angle X-ray scattering (SAXS) showed that the purified N protein is largely a dimer in solution. CD spectra showed that it has a high percentage of disordered region at room temperature while it was best structured at 55 degrees C, suggesting its structural dynamics. Fluorescence polarization assay showed it has non-specific nucleic acid binding capability, which raised a concern in using it as a diagnostic marker. Immunoblot assays confirmed the presence of IgA, IgM and IgG antibodies against N antigen in COVID-19 infection patients' sera, proving the importance of this antigen in host immunity and diagnostics.","Biochem Biophys Res Commun","Zeng, Weihong","Liu, Guangfeng","Ma, Huan","Zhao, Dan","Yang, Yunru","Liu, Muziying","Mohammed, Ahmed","Zhao, Changcheng","Yang, Yun","Xie, Jiajia","Ding, Chengchao","Ma, Xiaoling","Weng, Jianping","Gao, Yong","He, Hongliang","Jin, Tengchuan","32416961"],"abstract":["The nucleocapsid (N) protein is an important antigen for coronavirus, which participate in RNA package and virus particle release. In this study, we expressed the N protein of SARS-CoV-2 and characterized its biochemical properties. Static light scattering, size exclusive chromatography, and small-angle X-ray scattering (SAXS) showed that the purified N protein is largely a dimer in solution. CD spectra showed that it has a high percentage of disordered region at room temperature while it was best structured at 55 degrees C, suggesting its structural dynamics. Fluorescence polarization assay showed it has non-specific nucleic acid binding capability, which raised a concern in using it as a diagnostic marker. Immunoblot assays confirmed the presence of IgA, IgM and IgG antibodies against N antigen in COVID-19 infection patients' sera, proving the importance of this antigen in host immunity and diagnostics."],"journal":"Biochem Biophys Res Commun","authors":["Zeng, Weihong","Liu, Guangfeng","Ma, Huan","Zhao, Dan","Yang, Yunru","Liu, Muziying","Mohammed, Ahmed","Zhao, Changcheng","Yang, Yun","Xie, Jiajia","Ding, Chengchao","Ma, Xiaoling","Weng, Jianping","Gao, Yong","He, Hongliang","Jin, Tengchuan"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32416961","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.bbrc.2020.04.136","keywords":["antigenicity","covid-19","nucleocapsid protein","sars-cov-2","saxs","structure and function"],"topics":["Mechanism"],"weight":1,"_version_":1667058206853038080,"score":426.3157}]}